Braun Stacey Associates Inc. Takes $11.87 Million Position in IQVIA Holdings Inc. $IQV

Braun Stacey Associates Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the first quarter, Holdings Channel.com reports. The fund purchased 69,628 shares of the medical research company’s stock, valued at approximately $11,874,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. Riverstone Advisors LLC increased its position in IQVIA by 12.2% in the first quarter. Riverstone Advisors LLC now owns 1,374 shares of the medical research company’s stock worth $234,000 after buying an additional 149 shares during the period. Louisiana State Employees Retirement System bought a new position in shares of IQVIA during the first quarter worth about $1,467,000. Contravisory Investment Management Inc. acquired a new stake in shares of IQVIA in the 1st quarter worth about $65,000. Kestra Private Wealth Services LLC bought a new stake in IQVIA in the 1st quarter valued at about $380,000. Finally, Davis Investment Partners LLC bought a new stake in IQVIA in the 1st quarter valued at about $553,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $191.12 on Friday. The firm has a market capitalization of $31.90 billion, a PE ratio of 23.68, a P/E/G ratio of 1.64 and a beta of 1.21. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a 50-day moving average price of $174.43 and a 200 day moving average price of $190.07. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

Several research firms have commented on IQV. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research report on Friday, March 6th. HSBC set a $210.00 price target on IQVIA in a report on Wednesday, June 3rd. Royal Bank Of Canada started coverage on IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.